These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 29483209)
1. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Ikeda S; Lim JS; Kurzrock R Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209 [TBL] [Abstract][Full Text] [Related]
2. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers. Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272 [TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401 [TBL] [Abstract][Full Text] [Related]
4. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931 [TBL] [Abstract][Full Text] [Related]
5. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340 [TBL] [Abstract][Full Text] [Related]
6. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595 [TBL] [Abstract][Full Text] [Related]
7. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Ikeda S; Tsigelny IF; Skjevik ÅA; Kono Y; Mendler M; Kuo A; Sicklick JK; Heestand G; Banks KC; Talasaz A; Lanman RB; Lippman S; Kurzrock R Oncologist; 2018 May; 23(5):586-593. PubMed ID: 29487225 [TBL] [Abstract][Full Text] [Related]
8. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639 [TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636 [TBL] [Abstract][Full Text] [Related]
10. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
11. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study. Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635 [TBL] [Abstract][Full Text] [Related]
12. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003 [TBL] [Abstract][Full Text] [Related]
13. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351 [No Abstract] [Full Text] [Related]
14. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy. Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552 [TBL] [Abstract][Full Text] [Related]
15. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer. Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757 [No Abstract] [Full Text] [Related]
16. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963 [TBL] [Abstract][Full Text] [Related]
17. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing. Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147 [TBL] [Abstract][Full Text] [Related]
18. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585 [TBL] [Abstract][Full Text] [Related]
19. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949 [TBL] [Abstract][Full Text] [Related]
20. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]